Product
BAY2433334
3 clinical trials
3 indications
Indication
Myocardial InfarctionIndication
Atrial FibrillationIndication
Acute Non-cardioembolic Ischemic StrokeClinical trial
Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate the Efficacy and Safety of BAY 2433334 in Patients Following an Acute Myocardial InfarctionStatus: Completed, Estimated PCD: 2022-02-21
Clinical trial
Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study to Compare the Safety of the Oral FXIa Inhibitor BAY2433334 to Apixaban in Patients With Atrial FibrillationStatus: Completed, Estimated PCD: 2021-10-08
Clinical trial
Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate Efficacy and Safety of BAY2433334 in Patients Following an Acute Non-cardioembolic Ischemic StrokeStatus: Completed, Estimated PCD: 2022-02-18